Literature DB >> 16374035

Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001.

Matthew D Redelings1, Lucie McCoy, Frank Sorvillo.   

Abstract

Multiple sclerosis (MS) is a neurodegenerative condition that can result in cognitive and physical disability and shortened life expectancy. However, population-based information is lacking regarding the mortality burden from MS in the United States. We investigated trends in MS mortality rates and examined important comorbidities in the United States from 1990 to 2001. MS deaths were matched by age, sex, and race/ethnicity with randomly selected deaths from other conditions for matched odds ratio comparisons. The overall age-adjusted mortality rate from MS was 1.44/100,000 population. MS mortality rates increased throughout the study period. MS mortality rates were higher in whites than in any other racial/ethnic group, followed by Blacks, Hispanics, American Indians/Alaska Natives, and Asians and Pacific Islanders. Observed mortality rates were more than 10 times lower in Asians and Pacific Islanders than in whites. The odds of pressure ulcers, urinary tract infections, and pneumonia/influenza being reported on the death certificate were higher in MS deaths than in matched controls. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 16374035     DOI: 10.1159/000090444

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  30 in total

1.  Factors associated with health-related quality of life among older people with multiple sclerosis.

Authors:  Marijean Buhse; Wendy M Banker; Lynn M Clement
Journal:  Int J MS Care       Date:  2014

2.  Effects of a 10-week inspiratory muscle training program on lower-extremity mobility in people with multiple sclerosis: a randomized controlled trial.

Authors:  Lucinda Pfalzer; Donna Fry
Journal:  Int J MS Care       Date:  2011

3.  No human protein is exempt from bacterial motifs, not even one.

Authors:  Brett Trost; Guglielmo Lucchese; Angela Stufano; Mik Bickis; Anthony Kusalik; Darja Kanduc
Journal:  Self Nonself       Date:  2010-10

4.  Six-minute walk test for persons with mild or moderate disability from multiple sclerosis: performance and explanatory factors.

Authors:  Jane L Wetzel; Donna K Fry; Lucinda A Pfalzer
Journal:  Physiother Can       Date:  2011-04-13       Impact factor: 1.037

5.  Multiple cause of death analysis in multiple sclerosis: A population-based study.

Authors:  Katharine Harding; Feng Zhu; Mohammed Alotaibi; Thomas Duggan; Helen Tremlett; Elaine Kingwell
Journal:  Neurology       Date:  2020-01-13       Impact factor: 9.910

6.  Estriol Reduces Pulmonary Immune Cell Recruitment and Inflammation to Protect Female Mice From Severe Influenza.

Authors:  Meghan S Vermillion; Rebecca L Ursin; Sarah E Attreed; Sabra L Klein
Journal:  Endocrinology       Date:  2018-09-01       Impact factor: 4.736

7.  Intensive care unit admission in multiple sclerosis: increased incidence and increased mortality.

Authors:  Ruth Ann Marrie; Charles N Bernstein; Christine A Peschken; Carol A Hitchon; Hui Chen; Randy Fransoo; Allan Garland
Journal:  Neurology       Date:  2014-05-07       Impact factor: 9.910

8.  Cervical spinal demyelination with ethidium bromide impairs respiratory (phrenic) activity and forelimb motor behavior in rats.

Authors:  N L Nichols; A M Punzo; I D Duncan; G S Mitchell; R A Johnson
Journal:  Neuroscience       Date:  2012-11-14       Impact factor: 3.590

9.  Trends in death certification for multiple sclerosis, motor neuron disease, Parkinson's disease and epilepsy in English populations 1979-2006.

Authors:  Michael J Goldacre; Marie Duncan; Myfanwy Griffith; Martin R Turner
Journal:  J Neurol       Date:  2009-11-28       Impact factor: 4.849

10.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; James Blanchard; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-08-01       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.